Philippines vs Sierra Leone: Average cost of multi drug-resistant tuberculosis treatment
Philippines
310 constant 2022 US$
in 2024
Sierra Leone
369 constant 2022 US$
in 2024
Philippines rank
89th
Sierra Leone rank
88th
Average cost of multi drug-resistant tuberculosis treatment over time
- Philippines
- Sierra Leone
How they compare
Sierra Leone currently reports 369 constant 2022 US$ against 310 constant 2022 US$ in Philippines, a difference of 59 constant 2022 US$.
That makes Sierra Leone's figure about 1.2 times Philippines's.
The two have swapped places 3 times across 6 shared years of data; in 2017 it was Philippines ahead.
Philippines ranks 89th and Sierra Leone ranks 88th of 92 countries.
Philippines has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Philippines | Sierra Leone | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 4,921 constant 2022 US$ | 1,403 constant 2022 US$ | 3,518 constant 2022 US$ | Philippines |
| 2020s | 2.26 million constant 2022 US$ | 1,564 constant 2022 US$ | 2.26 million constant 2022 US$ | Philippines |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Philippines or Sierra Leone?
- Sierra Leone, at 369 constant 2022 US$ against 310 constant 2022 US$ in Philippines as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Philippines and Sierra Leone?
- 59 constant 2022 US$, with Sierra Leone ahead.
- How many years of comparable data are there for Philippines and Sierra Leone?
- 6 years are reported by both, from 2017 to 2024.
- How do Philippines and Sierra Leone rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Philippines ranks 89th and Sierra Leone ranks 88th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.